Cargando…

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria

Cefiderocol is a parenteral siderophore cephalosporin with a catechol-containing 3′ substituent. We evaluated its MICs against Gram-negative bacteria, using iron-depleted Mueller-Hinton broth. The panel comprised 305 isolates of Enterobacterales, 111 of Pseudomonas aeruginosa, and 99 of Acinetobacte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mushtaq, Shazad, Sadouki, Zahra, Vickers, Anna, Livermore, David M., Woodford, Neil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Susceptibility
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674041/ https://www.ncbi.nlm.nih.gov/pubmed/32958717 http://dx.doi.org/10.1128/AAC.01582-20

Ejemplares similares

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
por: Hackel, Meredith A., et al.
Publicado: (2017)

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes
por: Hackel, Meredith A., et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
por: Rolston, Kenneth V. I., et al.
Publicado: (2020)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates
por: Goldstein, Ellie J. C., et al.
Publicado: (2013)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens
por: Shortridge, Dee, et al.
Publicado: (2021)

In Vitro Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019)
por: Li, Xuechun, et al.
Publicado: (2022)

Accuracy of Direct Antimicrobial Susceptibility Testing of Gram-Negative Bacteria from Positive Blood Cultures Using MicroScan System and Value of Using Expert Rules for β-Lactam Agents
por: Jacobs, Michael R., et al.
Publicado: (2022)

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
por: Karlowsky, James A., et al.
Publicado: (2022)

Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
por: Khan, Ayesha, et al.
Publicado: (2021)

252 S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria
por: Tsuji, Masakatsu, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
por: Katsube, Takayuki, et al.
Publicado: (2019)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
por: Sato, Takafumi, et al.
Publicado: (2019)

Selective Conditions for a Multidrug Resistance Plasmid Depend on the Sociality of Antibiotic Resistance
por: Bottery, Michael J., et al.
Publicado: (2016)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

1285. Outcomes in Patients with Gram-Negative Bacteremia from Phase 2 and Phase 3 Clinical Trials of Cefiderocol, a Novel Siderophore Cephalosporin
por: Kinoshita, David PatersonDavid PatersonMasahiro, et al.
Publicado: (2020)

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
por: Katsube, Takayuki, et al.
Publicado: (2019)

Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh
por: Rahman, Arfatur, et al.
Publicado: (2017)

Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018
por: Le, Wenjing, et al.
Publicado: (2021)

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
por: Freeman, Jane, et al.
Publicado: (2015)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
por: Hussain, Abid
Publicado: (2021)

In Vitro Susceptibility and Resistance of Mycoplasma genitalium to Nitroimidazoles
por: Wood, Gwendolyn E., et al.
Publicado: (2023)

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples
por: Carcione, Davide, et al.
Publicado: (2021)

In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila
por: Dubois, Jacques, et al.
Publicado: (2020)

Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
por: Mukherjee, Devika, et al.
Publicado: (2017)

Decreased In Vitro Artemisinin Sensitivity of Plasmodium falciparum across India
por: Chakrabarti, Rimi, et al.
Publicado: (2019)

In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
por: Arendrup, Maiken Cavling, et al.
Publicado: (2015)

In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen
por: Hardy, Dwight J., et al.
Publicado: (2016)

Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro
por: Li, Wei, et al.
Publicado: (2017)

In Vitro Susceptibility to Closthioamide among Clinical and Reference Strains of Neisseria gonorrhoeae
por: Miari, Victoria F., et al.
Publicado: (2017)

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
por: Hackel, Meredith A., et al.
Publicado: (2017)

Development and Validation of an In Vitro Resazurin-Based Susceptibility Assay against Madurella mycetomatis
por: Abd Algaffar, S. O., et al.
Publicado: (2021)

The in vitro effect of new combinations of carbapenem–β-lactamase inhibitors for Mycobacterium abscessus
por: Fröberg, Gabrielle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f6i1mdjf3tgb3ai4nqu8i3sahl